-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab for the treatment of atopic dermatitis.
Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab.
Clinical effect of treatment of atopic dermatitis 48.
4% of patients in the 200 mg abrocitinib group, 36.
6% of the 100 mg abrocitinib group, 36.
5% of the dupilumab group, and 14.
0% of the placebo group had an IGA response at week 12; EASI at week 12 -75 response rates were 70.
3%, 58.
7%, 58.
1% and 27.
1%.
48.
4% of the 200mg abrocitinib group, 36.
6% of the 100mg abrocitinib group, 36.
5% of the dupilumab group, and 14.
0% of the placebo group had an IGA response at week 12; the EASI-75 response rate at week 12 was 70.
3%, respectively , 58.
7%, 58.
1% and 27.
1%.
Compared with placebo, abrocitinib can significantly improve the signs and symptoms of moderate to severe atopic dermatitis.
In improving the itching response, the effect of 200mg abroctinib group is better than dupilumab.
Compared with placebo, abrocitinib can significantly improve moderate to severe atopic dermatitis.
The signs and symptoms of the 200mg abroctinib group are better than dupilumab in improving the itching response.
Original Source: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Leave a message here
Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab.
Clinical effect of treatment of atopic dermatitis 48.
4% of patients in the 200 mg abrocitinib group, 36.
6% of the 100 mg abrocitinib group, 36.
5% of the dupilumab group, and 14.
0% of the placebo group had an IGA response at week 12; EASI at week 12 -75 response rates were 70.
3%, 58.
7%, 58.
1% and 27.
1%.
48.
4% of the 200mg abrocitinib group, 36.
6% of the 100mg abrocitinib group, 36.
5% of the dupilumab group, and 14.
0% of the placebo group had an IGA response at week 12; the EASI-75 response rate at week 12 was 70.
3%, respectively , 58.
7%, 58.
1% and 27.
1%.
Compared with placebo, abrocitinib can significantly improve the signs and symptoms of moderate to severe atopic dermatitis.
In improving the itching response, the effect of 200mg abroctinib group is better than dupilumab.
Compared with placebo, abrocitinib can significantly improve moderate to severe atopic dermatitis.
The signs and symptoms of the 200mg abroctinib group are better than dupilumab in improving the itching response.
Original Source: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Leave a message here
